O	0	1	A
O	2	13	neoadjuvant
O	13	14	,
O	15	25	randomized
O	25	26	,
O	27	31	open
O	31	32	-
O	32	37	label
O	38	43	phase
O	44	46	II
O	47	52	trial
O	53	55	of
B-intervention	56	64	afatinib
O	65	71	versus
B-control	72	83	trastuzumab
O	84	90	versus
B-control	91	100	lapatinib
O	101	103	in
O	104	112	patients
O	113	117	with
O	118	125	locally
O	126	134	advanced
O	135	139	HER2
O	139	140	-
O	140	148	positive
O	149	155	breast
O	156	162	cancer
O	162	163	.

O	164	176	Chemotherapy
O	177	179	is
O	180	188	standard
O	189	200	neoadjuvant
O	201	210	treatment
O	211	213	of
O	214	216	LA
O	217	219	BC
O	219	220	.

O	221	229	Patients
O	230	234	with
O	235	239	HER2
O	239	240	-
O	240	248	positive
O	249	251	BC
O	252	259	require
O	260	268	targeted
O	269	276	therapy
O	276	277	.

O	278	289	Trastuzumab
O	290	293	and
O	294	304	pertuzumab
O	304	305	,
O	306	311	which
O	312	318	target
O	319	323	HER2
O	323	324	,
O	325	329	with
O	330	342	chemotherapy
O	343	346	are
O	347	355	approved
O	356	358	as
O	359	370	neoadjuvant
O	371	378	therapy
O	378	379	,
O	380	387	however
O	387	388	,
O	389	399	treatments
O	400	404	with
O	405	414	different
O	415	425	mechanisms
O	426	428	of
O	429	435	action
O	436	441	might
O	442	449	provide
O	450	451	a
O	452	459	broader
O	460	465	range
O	466	468	of
O	469	477	activity
O	477	478	.

O	479	481	In
O	482	486	this
O	487	492	study
O	493	495	we
O	496	505	evaluated
O	506	509	the
O	510	518	efficacy
O	519	522	and
O	523	529	safety
O	530	532	of
O	533	536	the
O	537	549	irreversible
O	550	554	ErbB
O	555	561	family
O	562	569	blocker
O	570	578	afatinib
O	578	579	,
O	580	586	versus
O	587	598	trastuzumab
O	599	601	or
O	602	611	lapatinib
O	612	614	in
O	615	618	the
O	619	630	neoadjuvant
O	631	640	treatment
O	641	643	of
O	644	648	HER2
O	648	649	-
O	649	657	positive
O	657	658	,
O	659	661	LA
O	662	664	BC
O	664	665	.

B-eligibility	666	675	Treatment
I-eligibility	675	676	-
I-eligibility	676	681	naive
I-eligibility	681	682	,
I-eligibility	683	687	HER2
I-eligibility	687	688	-
I-eligibility	688	696	positive
I-eligibility	697	699	BC
I-eligibility	700	708	patients
I-eligibility	709	713	with
I-eligibility	714	719	stage
I-eligibility	720	724	IIIA
I-eligibility	724	725	,
I-eligibility	726	727	B
I-eligibility	727	728	,
I-eligibility	729	730	C
I-eligibility	731	733	or
I-eligibility	734	746	inflammatory
I-eligibility	747	754	disease
O	755	759	were
O	760	770	randomized
O	771	772	1
O	772	773	:
O	773	774	1
O	774	775	:
O	775	776	1
O	777	779	to
O	780	785	daily
O	786	794	afatinib
O	795	796	(
O	796	798	50
O	799	801	mg
O	801	802	)
O	802	803	,
O	804	813	lapatinib
O	814	815	(
O	815	819	1500
O	820	822	mg
O	822	823	)
O	823	824	,
O	825	827	or
O	828	834	weekly
O	835	846	trastuzumab
O	847	848	(
O	848	849	4
O	850	852	mg
O	852	853	/
O	853	855	kg
O	856	863	loading
O	864	868	dose
O	868	869	,
O	870	874	then
O	875	876	2
O	877	879	mg
O	879	880	/
O	880	882	kg
O	882	883	/
O	883	885	wk
O	885	886	)
O	887	890	for
O	891	892	6
O	893	898	weeks
O	899	904	until
O	905	912	surgery
O	913	915	or
O	916	922	follow
O	922	923	-
O	923	925	up
O	926	937	neoadjuvant
O	938	947	treatment
O	947	948	.

O	949	952	The
O	953	960	primary
O	961	964	end
O	965	970	point
O	971	974	was
B-outcome-Measure	975	984	objective
I-outcome-Measure	985	993	response
I-outcome-Measure	994	998	rate
O	999	1008	according
O	1009	1011	to
O	1012	1020	Response
O	1021	1031	Evaluation
O	1032	1040	Criteria
O	1041	1043	in
O	1044	1049	Solid
O	1050	1056	Tumors
O	1057	1058	(
O	1058	1065	version
O	1066	1067	1
O	1067	1068	.
O	1068	1069	0
O	1069	1070	)
O	1070	1071	.

O	1072	1083	Recruitment
O	1084	1087	was
O	1088	1095	stopped
O	1096	1101	early
O	1102	1109	because
O	1110	1112	of
O	1113	1117	slow
O	1118	1125	patient
O	1126	1136	enrollment
O	1136	1137	;
B-total-participants	1138	1140	29
O	1141	1149	patients
O	1150	1154	were
O	1155	1165	randomized
O	1166	1168	to
O	1169	1177	afatinib
O	1178	1179	(
O	1179	1180	n
O	1181	1182	=
B-intervention-participants	1183	1185	10
O	1185	1186	)
O	1186	1187	,
O	1188	1197	lapatinib
O	1198	1199	(
O	1199	1200	n
O	1201	1202	=
B-control-participants	1203	1204	8
O	1204	1205	)
O	1205	1206	,
O	1207	1209	or
O	1210	1221	trastuzumab
O	1222	1223	(
O	1223	1224	n
O	1225	1226	=
B-control-participants	1227	1229	11
O	1229	1230	)
O	1230	1231	.

B-outcome	1232	1241	Objective
I-outcome	1242	1250	response
O	1251	1254	was
O	1255	1259	seen
O	1260	1262	in
B-iv-bin-abs	1263	1264	8
O	1265	1273	afatinib
O	1273	1274	-
O	1274	1275	,
B-cv-bin-abs	1276	1277	6
O	1278	1287	lapatinib
O	1287	1288	-
O	1288	1289	,
O	1290	1293	and
B-cv-bin-abs	1294	1295	4
O	1296	1307	trastuzumab
O	1307	1308	-
O	1308	1315	treated
O	1316	1324	patients
O	1324	1325	.

O	1326	1332	Eleven
O	1333	1341	patients
O	1342	1345	had
B-outcome	1346	1352	stable
I-outcome	1353	1360	disease
I-outcome	1361	1362	(
I-outcome	1362	1366	best
I-outcome	1367	1375	response
I-outcome	1375	1376	)
O	1376	1377	;
B-iv-bin-abs	1378	1379	1
O	1380	1389	lapatinib
O	1389	1390	-
O	1391	1394	and
B-iv-bin-abs	1395	1396	1
O	1397	1408	trastuzumab
O	1408	1409	-
O	1409	1416	treated
O	1417	1424	patient
O	1425	1428	had
B-outcome	1429	1440	progressive
I-outcome	1441	1448	disease
O	1448	1449	.

O	1450	1453	All
B-iv-bin-abs	1454	1456	10
O	1457	1465	afatinib
O	1465	1466	-
O	1466	1473	treated
O	1474	1482	patients
O	1483	1494	experienced
B-outcome	1495	1499	drug
I-outcome	1499	1500	-
I-outcome	1500	1507	related
I-outcome	1508	1515	adverse
I-outcome	1516	1522	events
O	1523	1524	(
O	1524	1532	commonly
B-outcome	1533	1541	diarrhea
I-outcome	1541	1542	,
I-outcome	1543	1553	dermatitis
I-outcome	1554	1563	acneiform
I-outcome	1563	1564	,
I-outcome	1565	1568	and
I-outcome	1569	1579	paronychia
O	1579	1580	)
O	1581	1587	versus
B-cv-bin-abs	1588	1589	6
O	1590	1592	of
B-control-participants	1593	1594	8
O	1595	1604	lapatinib
O	1604	1605	-
O	1606	1607	(
B-outcome	1607	1615	diarrhea
I-outcome	1616	1619	and
I-outcome	1620	1624	rash
O	1624	1625	)
O	1626	1629	and
B-cv-bin-abs	1630	1631	5
O	1632	1634	of
B-control-participants	1635	1637	11
O	1638	1649	trastuzumab
O	1649	1650	-
O	1650	1657	treated
O	1658	1666	patients
O	1667	1668	(
B-outcome	1668	1676	vomiting
I-outcome	1677	1680	and
I-outcome	1681	1691	arthralgia
O	1691	1692	)
O	1692	1693	.

O	1694	1702	Afatinib
O	1703	1715	demonstrated
O	1716	1724	clinical
O	1725	1733	activity
O	1734	1738	that
O	1739	1747	compared
O	1748	1757	favorably
O	1758	1760	to
O	1761	1772	trastuzumab
O	1773	1776	and
O	1777	1786	lapatinib
O	1787	1790	for
O	1791	1802	neoadjuvant
O	1803	1812	treatment
O	1813	1815	of
O	1816	1820	HER2
O	1820	1821	-
O	1821	1829	positive
O	1830	1832	BC
O	1832	1833	,
O	1834	1838	with
O	1839	1840	a
O	1841	1847	safety
O	1848	1855	profile
O	1856	1866	consistent
O	1867	1871	with
O	1872	1881	epidermal
O	1882	1888	growth
O	1889	1895	factor
O	1896	1904	receptor
O	1905	1913	tyrosine
O	1914	1920	kinase
O	1921	1931	inhibitors
O	1931	1932	.
